DKB114, a mixture of Linn flower extract, effectively reduces serum uric acid level, suggesting its potential as a dietary supplement for hyperuricemia treatment.
Randomised Controlled Trial Gout Hyperuricemia Uric Acid
The research employed a randomized, double-blind, placebo-controlled clinical trial conducted across a span of 12 weeks. A total of 80 asymptomatic hyperuricemic subjects (serum uric acid level between 7.0-9.0 mg/dL) were selected and equally split into two groups. One group was administered DKB114, the investigational mixture of extracts, while the other group received a placebo.
After six weeks of administration, the levels of serum uric acid were evaluated, revealing no significant difference between the two groups. By the end of the 12th week, however, subjects in the DKB114 group exhibited a noticeably larger decrease in their serum uric acid levels when compared to the placebo group. Additionally, various other health indicators including C-reactive protein and apoprotein B levels showed significant trends favoring DKB114.
Further evaluations during the trial included clinical pathological tests, weight measurements and vital signs, and electrocardiogram tests which confirmed the safety of DKB114. No significant harmful effects or differences were detected in comparison to the placebo group. This concludes the positive impact and safe use of DKB114 for patients with elevated serum uric acid levels.
View Article